The Center for Biosimilars® recaps the top 5 articles for the week of May 7, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 7.
Number 5: A bibliometric analysis demonstrates that the quality and quantity of research on biosimilars is on the rise.
Number 4: Biosimilar developer Coherus announced that it has resubmitted a Biologics License Application for its pegfilgrastim biosimilar after receiving a Complete Response Letter for the drug in 2017.
Number 3: The European Medicines Agency’s 2017 report says that last year saw the agency’s highest-ever number of biosimilar applications.
Number 2: Research presented at the British Society for Rheumatology’s Annual Conference, held this month in Liverpool, United Kingdom, demonstrates that biosimilars are increasingly used as first-line treatment for juvenile idiopathic arthritis.
Number 1: Avalere has issued a new report that finds that utilization management strategies, including preferential formulary design and step therapy, are impacting the uptake of biosimilars in the United States.
Finally, last week, our e-newsletter asked for your thoughts on where the treatment of psoriasis is headed.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.